Press releases
Browse GSK global press releases issued since 2009. Search them by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
ViiV Healthcare receives Marketing Authorisation for Rukobia (fostemsavir), a first-in-class attachment inhibitor in combination with other antiretrovirals for the treatment of adults with multidrug-resistant HIV
Fostemsavir addresses a critical need for those with little to no treatment options left who are at risk of further disease progression
-
GSK delivers FY 2020 reported sales of £34 billion, +1% AER, +3% CER and Adjusted EPS of 115.9p, -6% AER, -4% CER, in line with guidance; Total EPS 115.5p, +23% AER
Strong growth of new and specialty products; on track to deliver two exciting new companies
-
GSK and CureVac to develop next generation mRNA COVID-19 vaccines
Companies aim to develop a multi-valent candidate vaccine to address emerging variants for pandemic and endemic use.
-
GSK, PATH, and Bharat Biotech sign product transfer agreement to help ensure long-term supply of RTS,S/AS01E malaria vaccine
The agreement recognises the track record and expertise of BBIL in developing and supplying vaccines against infectious diseases.
-
Lilly, Vir Biotechnology and GSK announce first patient dosed in expanded BLAZE-4 trial evaluating bamlanivimab (LY-CoV555) with VIR-7831 (GSK4182136) for COVID-19
Collaboration to evaluate a combination of two COVID-19 therapies in low-risk patients with mild to moderate COVID-19.
-
GSK ranks 1st in the 2021 Access to Medicine Index with leading R&D pipeline for priority diseases
Ranking reflects GSK leadership through access to its medicines and vaccines for people around the world.
-
ViiV Healthcare announces FDA approval of Cabenuva (cabotegravir, rilpivirine), the first and only complete long-acting regimen for HIV treatment
The approval is based on the pivotal phase III ATLAS and FLAIR studies that included more than 1,100 patients from 16 countries.
-
GSK and Novartis announce collaboration to support scientific research into genetic diversity in Africa
Combined funding commitment of GBP 2.8 million (USD 3.6 million) over five years.
-
GSK presents positive efficacy data of dostarlimab in mismatch repair-deficient (dMMR) solid cancers at ASCO Gastrointestinal Cancers Symposium
Data from GARNET cohort F shows a 38.7% objective response rate with dostarlimab in patients with dMMR advanced solid cancers
-
ViiV Healthcare receives EU Marketing Authorisation for the first-ever dispersible-tablet formulation of dolutegravir, Tivicay, a treatment for children living with HIV in Europe
The EU Marketing Authorisation follows the US Food and Drug Administration (FDA) approval of Tivicay PD in 2020.
-
Vir Biotechnology and GSK announce NHS-supported AGILE study to evaluate VIR-7832 in the early treatment of COVID-19
Second monoclonal antibody from Vir-GSK collaboration to be investigated as a potential COVID-19 treatment.
-
GSK, MMV filing for Kozenis (tafenoquine) in paediatric populations with Plasmodium vivax malaria accepted by Australian Therapeutic Goods Administration
The application includes data for a new, 50 mg tablet that can be dispersed in water and which was developed to facilitate use in children.
-
ViiV Healthcare announces the Marketing Authorisation of the first complete long-acting injectable HIV treatment in Europe
New treatment can enable people living with HIV to reduce the days they receive treatment from 365 to 12 or 6 per year
-
GSK and Ahren Announce Co-Led Series A Investment in Adrestia, and Multi-Project Discovery Collaboration with Each of the Five Projects Eligible To Receive Up To $230M (£172M) in Post Option Milestones
The multi-year collaboration agreement seeks to discover novel drug targets across a number of therapeutic areas
-
FDA approves GSK’s BENLYSTA as the first medicine for adult patients with active lupus nephritis in the US
Approval builds on nearly 10 years of experience in lupus
-
Vir Biotechnology and GSK announce start of NIH-sponsored ACTIV-3 trial evaluating VIR-7831 in hospitalised adults with COVID-19
Global Phase 3 trial will investigate the safety and efficacy of VIR-7831 in hospitalised adults with COVID-19
-
ViiV Healthcare announces positive CHMP opinion for Rukobia (fostemsavir), a first-in-class attachment inhibitor for the treatment of adults with multidrug-resistant HIV with few treatment options available
Fostemsavir addresses a critical unmet need in HIV care for those with little to no treatment options left.
-
Sanofi and GSK announce a delay in their adjuvanted recombinant protein-based COVID-19 vaccine programme to improve immune response in the elderly
Phase 1/2 interim results showed an immune response comparable to patients who recovered from COVID-19 in adults aged 18 to 49 years
-
FDA accepts GSK’s filing of Nucala (mepolizumab) for use in chronic rhinosinusitis with nasal polyps
If approved, Nucala would be the only treatment approved in the US for use in four eosinophil-driven diseases.
-
GSK starts phase 3 study of RSV maternal candidate vaccine
RSV is a leading cause of respiratory infections such as bronchiolitis and viral pneumonia in infants.
